Cryoablation for the primary treatment of clinically localized prostate cancer
BlueCross BlueShield Association
Record ID 32003000736
English
Authors' objectives:
This Assessment examines the available evidence on the outcomes and adverse effects of prostatic cryoablation for the primary treatment of clinically localized prostate cancer. Comparisons will be made to evidence on outcomes and adverse effects of conformal external beam radiotherapy and nerve-sparing radical prostatectomy for clinically localized prostate cancer.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Cryosurgery
- Prostatic Neoplasms
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.